Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $16.22.

A number of analysts recently commented on the stock. The Goldman Sachs Group lowered their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Virtus Fund Advisers LLC acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth approximately $29,000. Strs Ohio acquired a new position in shares of Amicus Therapeutics during the first quarter worth $30,000. Covestor Ltd lifted its holdings in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after purchasing an additional 2,312 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 3,497 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Amicus Therapeutics during the first quarter worth $53,000.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $6.22 on Wednesday. The firm has a fifty day moving average of $6.12 and a two-hundred day moving average of $7.85. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -69.10 and a beta of 0.51. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.